Bluebird bio — Conference Presentation (January 2021)
27 slides from Bluebird bio's conference presentation, Jan 11, 2021
Slide 1: Recoding For The Future
1 NASDAQ: BLUE Recoding For The Future January 2021 Company Presentation Exhibit 99.1
Slide 2: Forward-looking Statements
2 These slides and the accompanying oral presentation contain forward-looking statements and information. The use of words such as “may,” “might,” “will,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue,” and other similar exp
Slide 3: Our True North
3 Our True North THE FACES THE STORIES WHY?
Slide 4: A Decade of Advancing Programs Through the Clinic
4 L e n ti G lo b in f o r T D T id e -ce l (b b 2 1 2 1 ) 4 for 4: A Decade of Advancing Programs Through the Clinic to Deliver Life- Changing Medicines to Patients Robust Platform L e n ti G lo b in f o r SC D L e n ti-D C A L D ∞ PLATFORM To discuss
Slide 5: 2020 Silver Lining: De-risked Valley Crossing
5 2020 Silver Lining: De-risked “Valley Crossing” and Ready to Deliver for Patients Across All Products POC Data “Ted Talk” Deliver to Patients “Valley of Reality” Mature & Lever “Double Down” • Reg Approval • Scale / Globalize • P&R / Bus Model • Educate / Deploy • Mature Pipeline 2010-2017 2018-20
Slide 6: Unlocking Value for Patients and Shareholders
6 Unlocking Value for Patients and Shareholders bluebird plans to separate into two companies SCD TDT CALD BLUE SGD 2121/7 NextGen MM NHL AML Solids BLUE ONCO • Deliver 3 potentially-curative products to patients • Prove commercial model • Scale, leverage, expand the product platform • Launch ide-ce
Slide 7: Spin out bluebird oncology
7 Spin out bluebird oncology Create two independent publicly traded companies Anticipated tax–free transaction to close by EOY 2021 With ~$1.3B in cash, intent is for both companies to have sufficient runway at separation Launching Two Independent, Fully Integrated Commercial Stage Companies BLUE SG
Slide 8: Deliver For Patients Now. SGD Snapshot
8 Deliver For Patients Now. SGD Snapshot
Slide 9: Opportunity to Unlock Value with Increased Focus on Path to Patients
9 Opportunity to Unlock Value with Increased Focus on Path to Patients & Commercialization SGD Principles FOCUS: Execute near-term catalysts. Filings & launches. DELIVER: Prove commercial model. Novel pricing and reimbursement model for revenues in EU and US. GENERATE: Optimize COGS and reduce costs
Slide 10: Vision to Set the Standard for Successful Gene Therapy Commercialization
10 2023+ Gene-Therapy Leadership • U.S. SCD launch • Platform scale: Clinical, Commercial, Manufacturing • Geographic and indication expansion • Product optimization (RTC, mobilization) • Next generation research (in-vivo LVV) SCD: • U.S. BLA filing • Launch ready ZYNTEGLO: • U.S. approval and launc
Slide 11: Today's Strategic Foundation
11 TODAY’S STRATEGIC FOUNDATION… Foundational Building Blocks in Place with a De-risked Business Plan Commercial Infrastructure Regulatory Clarity Durability of Clinical Data Manufacturing Network Pricing and Reimbursement Model Advocacy & Relationships Reduced toxicity conditioning (Forty Seven/GIL
Slide 12: Manufacturing and Commercial Leverage
12 Manufacturing and Commercial Leverage Meaningful competitive advantages in TDT and SCD: Eligible Patients Anticipated on Label • Significantly longer safety follow up • Significantly longer durability data • Regulatory clarity • Experience with manufacturing scale-up • Commercial infrastructure i
Slide 13: Launch Time. ide-cel Just The Beginning. Oncology Snapshot
13 Launch Time. ide-cel Just The Beginning. Oncology Snapshot
Slide 14: Oncology Vision: Taking Flight
14 Oncology Vision: Taking Flight 1 2 3 BUILD & PARTNER: Mobilize cutting edge capabilities to enable launch goals (e.g., manufacturing) 4 CREATE: Optimize product engine to deliver 1-2 INDs per year 5 CRACK the solid tumors code: Deliver differential layered tech portfolio with best of breed partne
Slide 15: Unlocking the Full Potential for Cellular Therapy in Oncology
15 Clinical & correlative data educating biological hypothesis World-class LVV, mRNA & DP manufacturing capabilities Broad integrated tech & Cellular process development enables designed solutions Unlocking the Full Potential for Cellular Therapy in Oncology Complex problem….. …..demands a multi-par
Slide 16: One-to-Many Strategy: Recoding Traditional R&D
16 One-to-Many Strategy: Recoding Traditional R&D Nextgen Product Cycling Engine Designed to Rapidly Build, Test, Learn, and Improve PRODUCT CANDIDATES ACADEMIC COLLABORATORS PLATFORM TOOLS & TECH INDUSTRY LEADING PARTNERS 1:Many R&D Strategy RAPID CLINICAL TRANSLATION CAR TCR CCR DARIC ENHANCED COS
Slide 17: Oncology Product Candidates Pipeline
17 *ide-cel (bb2121) and bb21217 development in collaboration with BMS; MAGE-A4 development in collaboration with Regeneron and Medigene. PRODUCT CANDIDATES PROGRAM AREA PRECLINICAL PHASE 1/2 PHASE 2/3 ide-cel (bb2121)* PRODUCT CANDIDATES PROGRAM AREA PRECLINICAL PHASE 1/2 bb21217* NG MM CAR T PRODU
Slide 18: Our Broad and Deep Approach in Multiple Myeloma
18 Delivering to Patients: Our Broad and Deep Approach in Multiple Myeloma Nextgen Approaches Focused on Solving Meaningful and Definable Problems to Disrupt MM Care and Ide-cel BMS partnered BLUE owned
Slide 19: bbT369: Multi-layered Enhancements in bNHL
19 bbT369: Multi-layered Enhancements to Deliver Improved Potency and Patient Outcomes in bNHL Toledo-GCB DLBCL bbT369 CD19CAR Controls bbT369CD19 CAR Product designed to overcome mechanisms thought to limit efficacy of existing CAR T therapies and mediate potent anti-tumor activity with the goal of
Slide 20: CD33 Targeted Regulatable CAR T (DARIC33)
20 regulated targeting So lu ti o n CD33 Targeted Regulatable CAR T (DARIC33) hematopoietic risk HSC C h a ll e n g e Disease cells similar to & proximal to HSC Problem • Substantial unmet need in AML • Proximity of disease to HSCs = hematopoietic risk • CAR T cell that spares HSCs could transform A
Slide 21: Earlier Product Concept: MAGE-A4 TCR + TGFb Switch Receptor
21 Earlier Product Concept: Superior MAGE-A4 TCR + TGFb Switch Receptor* Engineered TCR with enhanced potency Product Concept TGFb TGFb Switch Receptor neutralizes TGFb Switch Receptor activates IL12R signaling Validating Data MAGEA4 TCR + Switch Receptor provides tumor control in a human melanoma m
Slide 22: By 2025, the leading oncology cell therapy company
22 By 2025, the leading oncology cell therapy company • Significant and growing ide-cel revenue • Path to financial sustainability • Strategic optionality BLUE Oncology Vision: An Innovative Cell Therapy R&D Company with First-in-Class BCMA Potential Blockbuster 1 The Cornerstone First Approved BCMA
Slide 23: Time to Run in 2021…
23 Time to Run in 2021…
Slide 24: Significant Near-term Catalysts Ahead for Each Company
24 2022 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 2021 Significant Near-term Catalysts Ahead for Each Company beti-cel U.S. BLA submission (mid-year) ide-cel KarMMa studies progressing and evolving ide-cel (bb2121) MM PDUFA, U.S. approval and launch eli-cel U.S. BLA submission (mid-year) LentiGlobin for SCD U.S. BLA
Slide 25: Launching Each Business from a Position of Financial Strength
25 Financial Overview: Launching Each Business from a Position of Financial Strength JAN 2021 SEPARATION ~EOY 2021 • Strong starting position – $1.3B cash – $0 Debt – Significant R&D cost share support from oncology partners (BMS/Regeneron) – Global rights to SGD products – Emerging commercial produ
Slide 26: Re-shaping bluebird to Deliver over Next Five Years
26 Re-shaping bluebird to Deliver over Next Five Years MAXIMIZE IMPACT • Deliver deeper therapeutic expertise • Disruption and focus favors patients PATIENTS ENGAGE AND ENABLE • Optimize diverging business needs • Operational simplification & focus • Rejuvenated and committed EMPLOYEES (“birds”) DEL
Slide 27: Simple Vision; Profound Mission
27 Simple Vision; Profound Mission R AD I C AL C AR E We care in a way that’s intense and truly sets us apart. T H I S I S P E R S O N AL Gene therapy is about saving lives one person at a time. And we are, each of us, personally all in. P I O N E E R S W I T H P U R P O S E We’re exploring new fron
bluebird bio — Conference Presentation (January 2021) on 6ix